{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+in+Human&page=28",
    "query": {
      "condition": "First in Human",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 1234,
    "total_pages": 124,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+in+Human&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+in+Human&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T02:43:00.528Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03526835",
      "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced/Metastatic Solid Tumors",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Gastroesophageal-junction Cancer",
        "NSCLC",
        "HNSCC",
        "Head and Neck Squamous Cell Carcinoma",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "MCLA-158",
          "type": "DRUG"
        },
        {
          "name": "MCLA-158 + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MCLA-158 + FOLFIRI",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MCLA-158 + FOLFOX",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 560,
      "start_date": "2018-05-02",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-19T02:43:00.528Z",
      "location_count": 31,
      "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 25 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03526835"
    },
    {
      "nct_id": "NCT04053673",
      "title": "Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "RBN-2397",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ribon Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2019-08-01",
      "completion_date": "2023-07-31",
      "has_results": false,
      "last_update_posted_date": "2023-03-28",
      "last_synced_at": "2026-11-19T02:43:00.528Z",
      "location_count": 11,
      "location_summary": "Aurora, Colorado • Denver, Colorado • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04053673"
    },
    {
      "nct_id": "NCT02748694",
      "title": "Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "TAK-041",
          "type": "DRUG"
        },
        {
          "name": "TAK-041 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 114,
      "start_date": "2016-05-09",
      "completion_date": "2019-09-22",
      "has_results": true,
      "last_update_posted_date": "2021-03-19",
      "last_synced_at": "2026-11-19T02:43:00.528Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748694"
    },
    {
      "nct_id": "NCT07066722",
      "title": "A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VH4524184",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifabutin",
          "type": "DRUG"
        },
        {
          "name": "Phenytoin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 126,
      "start_date": "2025-07-07",
      "completion_date": "2025-12-17",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-11-19T02:43:00.528Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07066722"
    },
    {
      "nct_id": "NCT05517837",
      "title": "A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "BMS-986421",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 46,
      "start_date": "2022-09-13",
      "completion_date": "2023-07-14",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-11-19T02:43:00.528Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05517837"
    },
    {
      "nct_id": "NCT01474681",
      "title": "Safety and Tolerability of HSC835 in Patients With Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelocytic Leukemia",
        "Acute Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndrome",
        "Chronic Lymphocytic Leukemia",
        "Marginal Zone Lymphoma",
        "Follicular Lymphomas",
        "Large-cell Lymphoma",
        "Lymphoblastic Lymphoma",
        "Burkitt's Lymphoma",
        "High Grade Lymphomas",
        "Mantle-cell Lymphoma",
        "Lymphoplasmacytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "HSC835",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "10 Years to 55 Years"
      },
      "enrollment_count": 27,
      "start_date": "2012-01-09",
      "completion_date": "2016-10-03",
      "has_results": true,
      "last_update_posted_date": "2020-12-30",
      "last_synced_at": "2026-11-19T02:43:00.528Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01474681"
    },
    {
      "nct_id": "NCT02941042",
      "title": "A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolism and Nutrition Disorder",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "NNC9204-1177",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 49,
      "start_date": "2016-10-10",
      "completion_date": "2017-09-30",
      "has_results": false,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-11-19T02:43:00.528Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02941042"
    },
    {
      "nct_id": "NCT05718557",
      "title": "Study of PYX-106 in Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PYX-106",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pyxis Oncology, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2023-05-23",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-11-19T02:43:00.528Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05718557"
    },
    {
      "nct_id": "NCT07909356",
      "title": "A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Advanced Solid Tumor Cancer",
        "Metastatic Pancreatic Cancer",
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "MC001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medicovestor, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-12",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-19T02:43:00.528Z",
      "location_count": 4,
      "location_summary": "Syracuse, New York • Huntersville, North Carolina • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07909356"
    },
    {
      "nct_id": "NCT04429542",
      "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Squamous Cell Carcinoma of Anal Canal",
        "Colorectal Cancer",
        "Squamous Cell Carcinoma of the Lung",
        "EGFR Amplification",
        "Epithelial Ovarian Cancer",
        "Pancreas Cancer",
        "Cutaneous Squamous Cell Carcinoma",
        "Head and Neck Neoplasms",
        "Carcinoma, Squamous Cell",
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "BCA101",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bicara Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 473,
      "start_date": "2020-06-01",
      "completion_date": "2028-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-19T02:43:00.528Z",
      "location_count": 15,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 10 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04429542"
    }
  ]
}